AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026090103
Submit to EJMO
Cite this article
2
Download
41
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW ARTICLE

The new era of hypertension management: Integrating precision medicine, digital health, and novel therapies

Yiling Shi1 ,  Sisi Li1 ,  Suning Hang1 ,  Chongchen Du1 ,  Honglei Dai1,2*
Show Less
1 Department of General Practice, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China
2 Department of General Practice, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
EJMO, 026090103 https://doi.org/10.36922/EJMO026090103
Received: 27 February 2026 | Revised: 9 March 2026 | Accepted: 18 March 2026 | Published online: 19 March 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Download PDF
XML
Cite
Abstract

Hypertension remains a leading global cause of cardiovascular morbidity and mortality, with a significant proportion of patients failing to achieve adequate blood pressure control despite established therapies. This underscores the urgent need for a paradigm shift toward more integrative and personalized management strategies. Our analysis, based on a narrative review of the current literature, reveals a transformed therapeutic landscape structured across four key pillars. Pharmacologically, novel agents including non-steroidal mineralocorticoid receptor antagonists (finerenone), aldosterone synthase inhibitors (baxdrostat, lorundrostat), and the siRNA therapy zilebesiran offer new mechanisms for resistant hypertension, while optimized low-dose single-pill and quadpill combinations significantly improve adherence. Device-based interventions, particularly renal denervation and baroreflex activation therapy, provide durable blood pressure reduction by modulating neurogenic pathways, supported by robust trial data, though their procedural risks require careful consideration. Precision medicine is advanced through the integration of circulating, genetic, and epigenetic biomarkers, enabling tailored therapy based on individual pathophysiological phenotypes. Digital health technologies, including wearable blood pressure monitors, telemedicine, and AI-driven predictive analytics, facilitate real-time monitoring, improve adherence, and enable proactive management. The future of hypertension care lies in an integrative, patient-centered model that synergistically combines pharmacological innovation, interventional procedures, biomarker-guided precision diagnostics, and digital health tools. Despite promising advances, challenges remain in cost-effectiveness, procedural safety, data integration, and equitable access. Addressing these barriers through coordinated efforts will be essential to translate this modern paradigm into sustainable clinical practice, ultimately optimizing blood pressure control and improving long-term cardiovascular outcomes.

Keywords
Hypertension
RAAS
Resistant Hypertension
Renal Denervation
Precision Medicine
Digital Health
Biomarkers
Pharmacotherapy
Funding
None.
Conflict of interest
The authors have disclosed no conflicts of interest.
References
  1. Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980. doi: 10.1016/s0140-6736(21)01330-1

 

  1. Fryar CD, Kit B, Carroll MD, Afful J. Hypertension prevalence, awareness, treatment, and control among adults age 18 and older: United States, August 2021–August 2023. NCHS Data Brief. 2024;(511):cs354233

 

  1. Carey RM, Moran AE, Whelton PK. Treatment ofHypertension. JAMA. 2022;328(18):1849. doi: 10.1001/jama.2022.19590

 

  1. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control. Circulation. 2016;134(6):441-450. doi: 10.1161/circulationaha.115.018912

 

  1. Fountain JH, Rout P. Physiology, Renin Angiotensin System. StatPearls Publishing. 2025. Aavailable from: https://www.ncbi.nlm.nih.gov/books/NBK470410/ [Last accessed on]

 

  1. Grassi G, Mark A, Esler M. The Sympathetic Nervous System Alterations in Human Hypertension. Circ Res. 2015;116(6):976-990. doi: 10.1161/circresaha.116.303604

 

  1. Valensi P. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications. Cardiovasc Diabetol. 2021;20(1). doi: 10.1186/s12933-021-01356-w

 

  1. DeLalio LJ, Sved AF, Stocker SD. Sympathetic Nervous System Contributions to Hypertension: Updates and Therapeutic Relevance. Can J Cardiol. 2020;36(5):712-720. doi: 10.1016/j.cjca.2020.03.003

 

  1. Drożdż D, Drożdż MWójcik M. Endothelial dysfunction as a factor leading to arterial hypertension. Pediatr Nephrol. 2023;38(9):2973-2985. doi: 10.1007/s00467-022-05802-z

 

  1. Touyz RM, Rios FJ, Alves-Lopes R, Neves KB, Camargo LLMontezano AC. Oxidative Stress: A Unifying Paradigm in Hypertension. Can J Cardiol. 2020;36(5):659-670. doi: 10.1016/j.cjca.2020.02.081

 

  1. Das D, Shruthi NR, Banerjee A, Jothimani G, Duttaroy AK, Pathak S. Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies. Front Nutr. 2023;10. doi: 10.3389/fnut.2023.1221438

 

  1. Yan Q, Liu S, Sun Y, et al. Targeting oxidative stress as a preventive and therapeutic approach for cardiovascular disease. J Transl Med. 2023;21(1):519. doi: 10.1186/s12967-023-04361-7

 

  1. Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J. 2013;34(13):951-961. doi: 10.1093/eurheartj/ehs455

 

  1. Shaman JA. The Future of Pharmacogenomics: Integrating Epigenetics, Nutrigenomics, and Beyond. J Pers Med. 2024;14(12). doi: 10.3390/jpm14121121

 

  1. Cooper-DeHoff RMJohnson    Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol. 2016;12(2):110-122. doi: 10.1038/nrneph.2015.176

 

  1. Li EC, Heran BSWright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;2014(8):Cd009096. doi: 10.1002/14651858.CD009096.pub2

 

  1. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. doi: 10.1016/s0140-6736(05)67185-1

 

  1. Ruggenenti P, Cravedi PRemuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol. 2012;23(12):1917- 1928. doi: 10.1681/asn.2012040390

 

  1. Hitomi H, Kiyomoto HNishiyama A. Angiotensin II and oxidative stress. Curr Opin Cardiol. 2007;22(4):311-315. doi: 10.1097/HCO.0b013e3281532b53

 

  1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993- 1004. doi: 10.1056/NEJMoa1409077

 

  1. Turner ST, Boerwinkle ESing CF. Context-dependent associations of the ACE I/D polymorphism with blood pressure. Hypertension. 1999;34(4):773-778. doi: 10.1161/01.hyp.34.4.773

 

  1. Godfraind T. Discovery and Development of Calcium Channel Blockers. Front Pharmacol. 2017;8. doi: 10.3389/fphar.2017.00286

 

  1. Jones KE, Hayden SL, Meyer HR, et al. The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations. Curr Issues Mol Biol. 2024;46(7):6315-6327. doi: 10.3390/cimb46070377

 

  1. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi: 10.1001/jama.288.23.2981

 

  1. Einhorn PT, Davis BR, Massie BM, et al. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and Am Heart J. 2007;153(1):42-53. doi: 10.1016/j.ahj.2006.10.012

 

  1. Steven S, Frenis K, Oelze M, et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. Oxid Med Cell Longev. 2019;2019. doi: 10.1155/2019/7092151

 

  1. Oates JT, Lopez D. Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. Int J Biomed Investig. 2018;1(2):1-16. doi: 10.31531/2581-4745.1000111

 

  1. Roush GC, Sica DA. Diuretics for Hypertension: A Review and Update. Am J Hypertens. 2016;29(10):1130-1137. doi: 10.1093/ajh/hpw030

 

  1. Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019;37(8):1574-1586. doi: 10.1097/hjh.0000000000002088

 

  1. Lee C-L, Zhang JFeng L. Molecular mechanisms of thiazide- like diuretics-mediated inhibition of the human Na-Cl cotransporter. Nat Commun. 2025;16(1):7740. doi: 10.1038/s41467-025-62714-w

 

  1. de Denus S, Rouleau JL, Mann DL, et al. A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. Pharmacogenomics J. 2017;17(2):192-200. doi: 10.1038/tpj.2016.4

 

  1. Fagerberg L, Hallström BM, Oksvold P, et al. Analysis of the human tissue-specific expression by genome- wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteom. 2014;13(2):397-406. doi: 10.1074/mcp.M113.035600

 

  1. Rodgers A, Salam A, Schutte AE, et al. Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension. J Am Coll Cardiol. 2024;84(24):2393-2403. doi: 10.1016/j.jacc.2024.08.025

 

  1. Rodgers A, Salam A, Schutte AE, et al. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024;404(10462):1536-1546. doi: 10.1016/s0140-6736(24)01744-6

 

  1. Chow CK, Atkins ER, Hillis GS, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398(10305):1043-1052. doi: 10.1016/S0140-6736(21)01922-X

 

  1. Huffman MD, Baldridge AS, Lazar D, et al. Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial. Hypertens Res. 2024;47(6):1668-1677. doi: 10.1038/s41440-024-01658-y

 

  1. Esimai O, Orji E, Lasisi A. Male contribution to infertility in Ile-Ife, Nigeria. Niger J Med. 2002;11(2):70-72.

 

  1. Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023;389(3):228-238. doi: 10.1056/NEJMoa2208391

 

  1. Bakris GL, Saxena M, Gupta A, et al. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024;331(9):740-749. doi: 10.1001/jama.2024.0728

 

  1. Hamrahian SM, Maarouf OH, Fülöp T. A Critical Review of Medication Adherence in Hypertension: Barriers and Facilitators Clinicians Should Consider. Patient Prefer Adherence. 2022;16(2749-2757. doi: 10.2147/ppa.S368784

 

  1. Morgan ES, Tami Y, Hu K, Brambatti M, Mullick AE, Geary RS, Bakris GL, Tsimikas S. Antisense Inhibition of Angiotensinogen With IONIS-AGT-L(Rx): Results of Phase 1 and Phase 2 Studies. JACC Basic Transl Sci. 2021;6(6):485- 496. doi: 10.1016/j.jacbts.2021.04.004

 

  1. Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023;388(5):395-405. doi: 10.1056/NEJMoa2213169

 

  1. Laffin LJ, Rodman D, Luther JM, et al. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA. 2023;330(12):1140-1150. doi: 10.1001/jama.2023.16029

 

  1. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263. doi: 10.1056/NEJMoa2110956

 

  1. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-2229. doi: 10.1056/NEJMoa2025845

 

  1. Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/valsartan versus olmesartan Japanese patients with essential hypertension: a randomized, multicenter study. HypertensRes. 2022;45(5):824-833. doi: 10.1038/s41440-021-00819-7

 

  1. Dunn ME, Kithcart A, Kim JH, et al. Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone. Nature. 2024;633(8030):654-661. doi: 10.1038/s41586-024-07903-1

 

  1. Arampatzis S, Funk GC, Leichtle AB, et al. Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department: a cross-sectional analysis. BMC Med. 2013;11. doi: 10.1186/1741-7015-11-83

 

  1. Borghi C, Cicero AFG, Agnoletti D, Fiorini G. Pathophysiology of cough with angiotensin-converting enzyme inhibitors: How to explain within-class differences? Eur J Intern Med. 2023;110:10-15. doi: 10.1016/j.ejim.2023.01.005

 

  1. Li Y, Sun JY, Guo QY, et al. Impact of Variability in Blood Pressure and Heart Rate on Beta-Blocker Adherence. J Clin Hypertens. 2025;27(5):e70065. doi: 10.1111/jch.70065

 

  1. Al-Janabi FLM, Moussa F, Taleb S, et al. Risk of developing hyperkalemia in patients with hypertension treated with combination antihypertensive therapy - a retrospective register-based study. Hypertens Res. 2025;48(1):378-387. doi: 10.1038/s41440-024-01894-2

 

  1. Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan  for  resistant  hypertension (PRECISION): a multicentre, blinded, randomised, parallel- group, phase 3 trial. Lancet. 2022;400(10367):1927-1937. doi: 10.1016/s0140-6736(22)02034-7

 

  1. Hanrahan JP, Wakefield JD, Wilson PJ, et al. A Randomized, Placebo-Controlled, Multiple-Ascending-Dose  Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8(5):564-575. doi: 10.1002/cpdd.627

 

  1. Hanrahan JP, Seferovic JP, Wakefield JD, et al. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 2020;63(4):733-743. doi: 10.1007/s00125-019-05062-x

 

  1. Ferdinand KC, Balavoine F, Besse B, et al. Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins. Circulation. 2019;140(2):138-146. doi: 10.1161/circulationaha.119.040070

 

  1. Haynes WG, Ferro CJWebb DJ. Bosentan in essential hypertension. N Engl J Med. 1998;339(5):346. doi: 10.1056/nejm199807303390513

 

  1. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens. 2002;15(7):583-589. doi: 10.1016/s0895-7061(02)02933-3

 

  1. Grassi G. Selective endothelin receptor blockade in resistant hypertension: results of the DORADO trial. Expert Opin Pharmacother. 2011;12(1):153-155. doi: 10.1517/14656566.2011.535812

 

  1. Webb DJ. DORADO: Opportunity Postponed. Hypertension. 2010;56(5):806-807. doi: 10.1161/HYPERTENSIONAHA.110.160952

 

  1. Danaietash P, Verweij P, Wang JG, et al. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan. J Clin Hypertens. 2022;24(7):804-813. doi: 10.1111/jch.14517

 

  1. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter- based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-1451. doi: 10.1016/s0140-6736(20)30554-7

 

  1. Liu M, Chen J, Liu C, Huang D, Ke J, Tang W, Huang SWu W. Catheter-based renal sympathetic denervation is effective in reducing office and ambulatory blood pressure in patients with resistant hypertension. Int J Cardiol. 2014;172(1):259- 260. doi: 10.1016/j.ijcard.2013.12.267

 

  1. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-1401. doi: 10.1056/NEJMoa1402670

 

  1. Straus S, Farah M, Pillai K, Siracuse JJ, Alsaigh T, Malas M. Uncontrolled hypertension is associated with complications and poorer outcomes after endovascular aneurysm repair. J Vasc Surg. 2025;81(3):606-612. doi: 10.1016/j.jvs.2024.11.030

 

  1. Mahfoud F, Mancia G, Schmieder R, et al. Renal Denervation in High-Risk Patients With Hypertension. J Am Coll Cardiol. 2020;75(23):2879-2888. doi: 10.1016/j.jacc.2020.04.036

 

  1. Fengler K, Rommel KP, Blazek S, et al. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN). Circulation. 2019;139(5):590-600. doi: 10.1161/circulationaha.118.037654

 

  1. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter- based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160-2170. doi: 10.1016/s0140-6736(17)32281-x

 

  1. Alnima T, de Leeuw PWKroon AA. Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments. Cardiol Res Pract. 2012;2012. doi: 10.1155/2012/587194

 

  1. Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55(3):619-626. doi: 10.1161/hypertensionaha.109.140665

 

  1. Wallbach M, Halbach M, Reuter H, et al. Baroreflex activation therapy in patients with prior renal denervation. J Hypertens. 2016;34(8):1630-1638. doi: 10.1097/hjh.0000000000000949

 

  1. Révész D, Rydenhag B, Ben-Menachem E. Complications and safety of vagus nerve stimulation: 25 years of experience at a single center. J Neurosurg Pediatr. 2016;18(1):97-104. doi: 10.3171/2016.1.Peds15534

 

  1. Tolu-Akinnawo O, Ray DN, Awosanya T, Nzerue C, Okafor H. Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review. Cureus. 2024;16(8):e66304. doi: 10.7759/cureus.66304

 

  1. Wong B, Kuwabara Y,Salavatian S. Neuromodulation of the Cardiac Autonomic Nervous System for Arrhythmia Treatment. Biomedicines. 2025;13(7). doi: 10.3390/biomedicines13071776

 

  1. Vase H, Mathiassen ON, Kaltoft A, et al. Catheter-based renal denervation for treatment of resistant hypertension. Dan Med J. 2012;59(6):A4439.

 

  1. Singh SP, Varghese KJ, Qureshi FM, Anderson MC, Foxworth J,Knuepfer MM. Catheter-based renal sympathetic nerve denervation on hypertension management outcomes. World J Radiol. 2022;14(7):238-248. doi: 10.4329/wjr.v14.i7.238

 

  1. Jordan J, Tank J, Heusser K,Reuter H. Baroreflex activation therapy through electrical carotid sinus stimulation. Auton Neurosci. 2024;256. doi: 10.1016/j.autneu.2024.103219

 

  1. Konstantinidis D, Iliakis P, Tatakis F, et al. Wearable blood pressure measurement devices and new approaches in hypertension management: the digital era. J Hum Hypertens. 2022;36(11):945-951. doi: 10.1038/s41371-022-00675-z

 

  1. Del Rio R, Marcus NJ, Schultz HD. Carotid chemoreceptor ablation improves survival in heart failure: rescuing autonomic control of cardiorespiratory function. J Am Coll Cardiol. 2013;62(25):2422-2430. doi: 10.1016/j.jacc.2013.07.079

 

  1. Adams ZH, Hart ECPatel NK. Deep brain stimulation for control of refractory hypertension. Auton Neurosci. 2025;260. doi: 10.1016/j.autneu.2025.103286

 

  1. Lobo MD, Sobotka PA, Stanton A, et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015;385(9978):1634- 1641. doi: 10.1016/s0140-6736(14)62053-5

 

  1. Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet. 2019;393(10175):1034-1044. doi: 10.1016/s0140-6736(18)31808-7

 

  1. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061

 

  1. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide- based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66-74. doi: 10.1001/jama.2013.7588

 

  1. Tain YL,Hsu CN. Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA)  and Symmetric Dimethylarginine (SDMA). Toxins. 2017;9(3). doi: 10.3390/toxins9030092

 

  1. Coca SG, Nadkarni GN, Huang Y, et al. Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease. J Am Soc Nephrol. 2017;28(9):2786- 2793. doi: 10.1681/asn.2016101101

 

  1. Rizzoni D, De Ciuceis C, Szczepaniak P, Paradis P, Schiffrin EL, Guzik TJ. Immune System and Microvascular Remodeling in Humans. Hypertension. 2022;79(4):691-705. doi: 10.1161/hypertensionaha.121.17955

 

  1. Sánchez-Cabo F, Rossello X, Fuster V, et al. Machine Learning Improves Cardiovascular Risk Definition for Young, Asymptomatic Individuals. J Am Coll Cardiol. 2020;76(14):1674-1685. doi: 10.1016/j.jacc.2020.08.017

 

  1. Litjens G, Sánchez CI, Timofeeva N, et al. Deep learning as a tool for increased accuracy and efficiency of histopathological diagnosis. Sci Rep. 2016;6(1):26286. doi: 10.1038/srep26286

 

  1. Ayuzawa N, Fujita T. The Mineralocorticoid Receptor in Salt-Sensitive Hypertension and Renal Injury. J Am Soc Nephrol. 2021;32(2):279-289. 10.1681/asn.2020071041

 

  1. Johnson JA,  Cavallari    Cardiovascular pharmacogenomics. Exp Physiol. 2005;90(3):283-289. doi: 10.1113/expphysiol.2004.028506

 

  1. Gonzalez-Vicente A, Saez F, Monzon CM, Asirwatham J, Garvin JL. Thick Ascending Limb Sodium Transport in the Pathogenesis of Hypertension. Physiol Rev. 2019;99(1):235- 309. doi: 10.1152/physrev.00055.2017

 

  1. Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019;394(10197):521-532. doi: 10.1016/s0140-6736(19)31276-0

 

  1. Padmanabhan S, Dominiczak AF. Genomics  of hypertension: the road to precision medicine. Nat Rev Cardiol. 2021;18(4):235-250. doi: 10.1038/s41569-020-00466-4

 

  1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339

 

  1. Yang T, Santisteban MM, Rodriguez V, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65(6):1331- 1340. doi: 10.1161/hypertensionaha.115.05315

 

  1. Kario K. Management of Hypertension in the Digital Era: Small Wearable Monitoring Devices for Remote Blood Pressure Monitoring. Hypertension. 2020;76(3):640-650. doi: 10.1161/hypertensionaha.120.14742

 

  1. Fujiwara T, McManus RJ, Kario K. Management of hypertension in the digital era: Perspectives and future directions. Hipertens Riesgo Vasc. 2022;39(2):79-91. doi: 10.1016/j.hipert.2022.01.004

 

  1. Johnson KB, Wei WQ, Weeraratne D, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021;14(1):86-93. doi: 10.1111/cts.12884

 

  1. Stergiou GS, Mukkamala R, Avolio A, et al. Cuffless blood pressure measuring devices: review and statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens. 2022;40(8):1449-1460. doi: 10.1097/hjh.0000000000003224

 

  1. Sharman JE, O’Brien E, Alpert B, et al. Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. J Hypertens. 2020;38(1):21-29. doi: 10.1097/hjh.0000000000002246

 

  1. McManus RJ, Little P, Stuart B, et al. Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial. BMJ. 2021;372:m4858. doi: 10.1136/bmj.m4858

 

  1. Sinou N, Sinou N, Koutroulakis S, Filippou D. The Role of Wearable Devices in Blood Pressure Monitoring and Hypertension Management: A Systematic Review. Cureus. 2024;16(12):e75050. doi: 10.7759/cureus.75050

 

  1. Ruan P, Todd JL, Zhao H, et al. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023;24(1):141. doi: 10.1186/s12931-023-02435-0

 

  1. Parati G, Stergiou GS, Bilo G, et al. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. J Hypertens. 2021;39(9):1742-1767. doi: 10.1097/hjh.0000000000002922

 

  1. Shaw RJ, Kaufman MA, Bosworth HB, et al. Organizational factors associated with readiness to implement and translate a primary care based telemedicine behavioral program to improve blood pressure control: the HTN-IMPROVE study. Implement Sci. 2013;8. doi: 10.1186/1748-5908-8-106

 

  1. Citoni B, Figliuzzi I, Presta V, Volpe M, Tocci G. Home Blood Pressure and Telemedicine: A Modern Approach for Managing Hypertension During and After COVID-19 Pandemic. High Blood Press Cardiovasc Prev. 2022;29(1):1- 14. doi: 10.1007/s40292-021-00492-4

 

  1. Eberly LA, Khatana SAM, Nathan AS, et al. Telemedicine Outpatient Cardiovascular Care During the COVID- 19 Pandemic: Bridging or Opening the Digital Divide? Circulation. 2020;142(5):510-512. doi: 10.1161/circulationaha.120.048185

 

  1. Noah B, Keller MS, Mosadeghi S, et al. Impact of remote patient monitoring on clinical outcomes: an updated meta analysis of randomized controlled trials. NPJ Digit Med. 2018;1(1). doi: 10.1038/s41746-017-0002-4

 

  1. Dorsey ER, Topol EJ. Telemedicine 2020 and the next decade. Lancet. 2020;395(10227):859. doi: 10.1016/s0140-6736(20)30424-4

 

  1. Koshimizu H, Kojima R, Okuno Y. Future possibilities for artificial intelligence in the practical management of hypertension. Hypertens Res. 2020;43(12):1327-1337. doi: 10.1038/s41440-020-0498-x

 

  1. Navar AM, Fine LJ, Ambrosius WT, et al. Earlier treatment in adults with high lifetime risk of cardiovascular diseases: What prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) Workshop. Am J Prev Cardiol. 2022;12:100430. doi: 10.1016/j.ajpc.2022.100430

 

  1. Xiao ZL, Yang M, Chen XB, Xie XM, Chen MF. Personalized antihypertensive treatment guided by pharmacogenomics in China. Cardiovasc Diagn Ther. 2022;12(5):635-645. doi: 10.21037/cdt-22-154

 

  1. Visco V, Izzo C, Mancusi C, et al. Artificial Intelligence in Hypertension Management: An Ace up Your Sleeve. J Cardiovasc Dev Dis. 2023;10(2):74. doi: 10.3390/jcdd10020074

 

  1. Char DS, Shah NH, Magnus D. Implementing Machine Learning in Health Care - Addressing Ethical Challenges. N Engl J Med. 2018;378(11):981-983. doi: 10.1056/NEJMp1714229

 

  1. Skalidis I, Maurizi N, Salihu A, Fournier S, Cook S, Iglesias JF, et al. Artificial Intelligence and Advanced Digital Health for Hypertension: Evolving Tools for Precision Cardiovascular Care. Medicina. 2025;61(9):1597. doi: 10.3390/medicina61091597

 

  1. Taddei S. Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence? Am J Cardiovasc Drugs. 2015;15(3):185-194. doi: 10.1007/s40256-015-0116-5

 

  1. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300. doi: 10.1016/j.amjmed.2008.09.038

 

  1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi: 10.1136/bmj.b1665

 

  1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi: 10.1161/hyp.0000000000000066

 

 

  1. Chomiuk T, Niezgoda N, Mamcarz AŚliż D. Physical activity in metabolic syndrome. Front Physiol. 2024;15. doi: 10.3389/fphys.2024.1365761

 

  1. Hughes JW, Fresco DM, Myerscough R, et al. Randomized controlled trial of mindfulness-based stress reduction for prehypertension. Psychosom Med. 2013;75(8):721-728. doi: 10.1097/PSY.0b013e3182a3e4e5

 

  1. Delles CHusi H. Systems Biology Approach in Hypertension Research. Methods Mol Biol. 2017;1527:69-79. doi: 10.1007/978-1-4939-6625-7_6

 

  1. Ni Y, Jia F. A Scoping Review of AI-Driven Digital Interventions in Mental Health Care: Mapping Applications Across Screening, Support, Monitoring, Prevention, and Clinical Education. Healthcare. 2025;13(10):1205. doi: 10.3390/healthcare13101205

 

  1. Savoia C, Volpe M, Grassi G, Borghi C, Agabiti Rosei E, Touyz RM. Personalized medicine-a modern approach for the diagnosis and management of hypertension. Clin Sci. 2017;131(22):2671-2685. doi: 10.1042/cs20160407

 

  1. Hypertension in Pregnancy. Obstetrics & Gynecology. 2013;122(5):1122-1131. doi: 10.1097/01.aog.0000437382.03963.88

 

  1. Hauspurg A, Jeyabalan A. Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2022;226(2s):S1211-s1221. doi: 10.1016/j.ajog.2020.10.027

 

  1. Katsi V, Skalis G, Vamvakou G, Tousoulis D, Makris T. Postpartum Hypertension. Curr Hypertens Rep. 2020;22(8):58. doi: 10.1007/s11906-020-01058-w

 

  1. Shen M, Tan H, Zhou S, Smith GN, Walker MC, Wen SW. Trajectory of blood pressure change during pregnancy and the role of pre-gravid blood pressure: a functional data analysis approach. Sci Rep. 2017;7(1):6227. doi: 10.1038/s41598-017-06606-0

 

  1. Stergiou GS, Palatini P, Asmar R, et al. Recommendations and Practical Guidance for performing and reporting validation studies according to the Universal Standard for the validation of blood pressure measuring devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO). J Hypertens. 2019;37(3):459-466.doi: 10.1097/hjh.0000000000002039

 

 

  1. O’Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731-1768. doi: 10.1097/HJH.0b013e328363e964

 

  1. Ditisheim A, Wuerzner G, Ponte B, et al. Prevalence of Hypertensive Phenotypes After Preeclampsia: A Prospective Cohort Study. Hypertension. 2018;71(1):103-109. doi: 10.1161/hypertensionaha.117.09799

 

  1. van den Born BH, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):37-46. doi: 10.1093/ehjcvp/pvy032

 

  1. Huhn EA, Kreienbühl A, Hoffmann I, Schoetzau A, Lange S, Martinez de Tejada B, Hund M, Hoesli ILapaire O. Diagnostic Accuracy of Different Soluble fms-Like Tyrosine Kinase 1 and Placental Growth Factor Cut-Off Values in the Assessment of Preterm and Term Preeclampsia: A Gestational Age Matched Case-Control Study. Front Med. 2018;5. doi: 10.3389/fmed.2018.00325

 

  1. Cerdeira AS, O’Sullivan J, Ohuma EO, et al. Performance of soluble fms-like tyrosine kinase-1-to-placental growth factor ratio of ≥85 for ruling in preeclampsia within 4 weeks. Am J Obstet Gynecol. 2021;224(3):322-323. doi: 10.1016/j.ajog.2020.11.007

 

  1. Wu R, Wang T, Gu R, et al. Hypertensive Disorders of Pregnancy and Risk of Cardiovascular Disease-Related Morbidity and Mortality: A Systematic Review and Meta- Analysis. Cardiology. 2020;145(10):633-647. doi: 10.1159/000508036

 

  1. Scher MS. Neurologic Sequelae Associated with Hypertensive Disorders of Pregnancy. Children. 2021;8(11). doi: 10.3390/children8110945

 

  1. Magee LA, Ramsay G, von Dadelszen P. What is the role of out-of-office BP measurement in hypertensive pregnancy? Hypertens Pregnancy. 2008;27(2):95-101. doi: 10.1080/10641950801950197

 

  1. Tucker KL, Mort S, Yu LM, et al. Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial. JAMA. 2022;327(17):1656-1665. doi: 10.1001/jama.2022.4712

 

  1. Williams B, Mancia G, Spiering W, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Hypertension. Blood Press. 2018;27(6):314-340. doi: 10.1080/08037051.2018.1527177

 

  1. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017;377(7):613-622. doi: 10.1056/NEJMoa1704559

 

  1. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014. doi: 10.1002/14651858.CD001059.pub4

 

  1. Antza C, Dimou C, Doundoulakis I, et al. The flipside of hydralazine in pregnancy: A systematic review and meta- analysis. Pregnancy Hypertens. 2020;19:177-186. doi: 10.1016/j.preghy.2020.01.011

 

  1. Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(9):1906-1916. doi: 10.1111/bcp.13649

 

  1. Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;2010(11):Cd000025. doi: 10.1002/14651858.CD000025.pub2

 

  1. Tita AT, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022;386(19):1781-1792. doi: 10.1056/NEJMoa2201295

 

  1. Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374(9694):979-988. doi: 10.1016/s0140-6736(09)60736-4

 

  1. Spaan J, Peeters L, Spaanderman M, Brown M. Cardiovascular risk management after a hypertensive disorder of pregnancy. Hypertension. 2012;60(6):1368-1373. doi: 10.1161/hypertensionaha.112.198812

 

  1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-237. doi: 10.1038/s41581-019-0244-2

 

  1. Moran AE, Odden MC, Thanataveerat A, et al. Cost effectiveness of hypertension therapy according to 2014 N Engl J Med. 2015;372(5):447-455. doi: 10.1056/NEJMsa1406751

 

  1. Kennelty KA, Polgreen LA, Carter BL. Team-Based Care with Pharmacists to Improve Blood Pressure: a Review of Recent Literature. Curr Hypertens Rep. 2018;20(1):1. doi: 10.1007/s11906-018-0803-0

 

  1. Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024;47(5):1099-1102. doi: 10.1038/s41440-024-01622-w
Next article in this issue
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept